Merck, a leader in science and technology, has announced the launch of its first GMP (Good Manufacturing Practices) compliant cell culture media (CCM) manufacturing line in China. The new facility, located at Merck’s Life Science Center in Nantong, represents a €6.6 million investment aimed at meeting the rising local demand for high-quality CCM used in biopharmaceuticals, vaccines, and innovative therapies.
This local production line will enable Chinese customers to access Merck’s proven CCM products and services with greater reliability and efficiency. Utilizing Merck’s extensive formulation expertise, the company designs tailored CCM solutions to enhance process consistency and efficiency.
Roy Wu, Managing Director of Merck China’s Life Science business sector, commented, “This investment not only expands Merck’s presence and capabilities in China but also underscores our dedication to advancing the local biopharma industry. The new manufacturing line is a testament to our commitment to improving patient care through our innovative approach and global expertise.”
The Nantong GMP facility uses components from qualified sources to ensure a seamless transition from pilot to commercial-scale production, supported by thorough regulatory documentation. In addition to customized dry powder CCM products, Merck will offer specialized technical and operational support to local biopharma manufacturers, helping to shorten time to market and reduce product lead times.
Cao Haifeng, Deputy Secretary of the NETDA Party Working Committee and Director of the NETDA Administrative Committee, stated, “The Nantong Economic and Technological Development Area (NETDA) is dedicated to accelerating the high-quality development of its biopharma industry. Merck’s Life Science Center in Nantong will make significant contributions to the regional biopharma ecosystem.”
Merck’s Life Science business provides a comprehensive range of solutions for both local and global biopharma customers. Alongside CCM, the portfolio includes cell lines, bioreactors, filters, resins, chromatographic materials, pharmaceutical raw materials, and excipients. These end-to-end process solutions are designed to support biopharma manufacturers from development through scale-up, advancing global health and benefiting patients worldwide.
